Effect of Addition of Mannitol to Bupivacaine on IANB Success and Post-endodontic Pain
Effect of Addition of 0.5 Mol/L Mannitol to 0.5% Bupivacaine on IANB Success and Post-endodontic Pain in Mandibular Molars With Irreversible Pulpitis: A Randomized Clinical Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients; age between 17-35 years old.
- Males or Females.
- Medically-free patients
- Patients suffering from symptomatic irreversible pulpitis without apical periodontitis in mandibular molar teeth.
- Positive patients' acceptance for participation in the study.
Exclusion Criteria:
- Patients who had any analgesic during proceeding 12 hours before the treatment.
- Teeth with necrotic, infected pulp, swelling or symptomatic apical periodontitis (apical abscess).
- Pregnant females.
- Patients with history of significant medical conditions (contraindication of mannitol use).
- Addiction
- Psycological disturbance.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: bupivacaine plus mannitol
0.5% bupivacaine with 1:200,000 epinephrine plus 1.5 ml of 0.5 mol/L mannitol
|
local anesthesia
Other Names:
|
|
Experimental: bupivacaine alone
0.5% bupivacaine with 1:200,000epinephrine alone
|
local anesthesia
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postoperative pain intensity ranging from 0-10 where 0 means no pain, 10 the worst pain
Time Frame: 6 hours
|
using pain scale ranging from 0-10 where 0 means no pain, 10 the worst pain
|
6 hours
|
|
Postoperative pain intensity ranging from 0-10 where 0 means no pain, 10 the worst pain
Time Frame: 12 hours
|
using pain scale ranging from 0-10 where 0 means no pain, 10 the worst pain
|
12 hours
|
|
Postoperative pain intensity ranging from 0-10 where 0 means no pain, 10 the worst pain
Time Frame: 24 hours
|
using pain scale ranging from 0-10 where 0 means no pain, 10 the worst pain
|
24 hours
|
|
Postoperative pain intensity ranging from 0-10 where 0 means no pain, 10 the worst pain
Time Frame: 48 hours
|
using pain scale ranging from 0-10 where 0 means no pain, 10 the worst pain
|
48 hours
|
|
Postoperative pain intensity ranging from 0-10 where 0 means no pain, 10 the worst pain
Time Frame: 72 hours
|
using pain scale ranging from 0-10 where 0 means no pain, 10 the worst pain
|
72 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Anesthetic success
Time Frame: 1 hour
|
yes or no
|
1 hour
|
|
lip numbness duration
Time Frame: 24 hours
|
recorded in hours
|
24 hours
|
|
Medication intake
Time Frame: 72 hours
|
yes or no
|
72 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CEBD-CU-2012-12-24
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.